Merck's sugammadex finally wins FDA panel backing; Novartis, Sanofi unveil new data at ACR; Weight-loss app no better than handouts, study finds; FDA tentatively OKs Collegium painkiller;

> Merck & Co.'s ($MRK) long-delayed anesthesia reversal agent, sugammadex, won a thumbs up from an FDA advisory panel Friday, with a final decision expected by Dec. 19. Report

> Novartis ($NVS), Sanofi ($SNY) and Regeneron ($REGN) were among the major drugmakers rolling out new data on their products and prospective products at the American College of Rheumatology meeting over the weekend. Release | Release | Release

> A weight-loss app was no better than a hard-copy pamphlet at helping obese young adults lose weight, Duke University researchers found in a study published in the journal Obesity. Report

> Collegium nabbed tentative FDA approval for its opioid painkiller Xtampza ER, but it can't launch till it resolves patent infringement suits with pain giant Purdue Pharma. Report

> GlaxoSmithKline's ($GSK) lupus drug Benlysta hit its goals in a new Phase III study, which compared the treatment to standard of care; the data showed 60% of patients in the Benlysta arm saw reduced disease activity compared with 48% in the control arm. Release

And Finally... Pfizer's ($PFE) tax accounting methods make its U.S. rate appear larger--by 7 percentage points--than it would if the drugmaker reported foreign earnings as other big corporations do, the Wall Street Journal reports. Story (sub. req.)

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Stinging from a previous trial failure in 2016, AstraZeneca's Brilinta topped solo aspirin in slicing CV risks in heart attack and stroke patients.

Taking over IL-23 inhibitor brazikumab marks a new endeavor for AstraZeneca, as does buying prescription drugs Zenpep and Viokace for Nestlé.